Rothschild & Co Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $203

Benzinga · 1d ago
Rothschild & Co analyst Jamie Clark initiates coverage on Guardant Health (NASDAQ:GH) with a Buy rating and announces Price Target of $203.